Malignant pleural mesothelioma (MPM) is a rapidly lethal cancer arising from the parietal
pleural mesothelium, and is associated with exposure to asbestos.
Once a rare disease, it is increasing in incidence in the UK and is presently more common
than cervical cancer. MPM is characterized by local invasion of adjacent structures including
the chest wall, mediastinum, diaphragm and pericardium resulting in progressive shortness of
Median survival with best supportive care alone is approximately 6-9 months and most cases of
mesothelioma present in the advanced setting. Therefore this trial will be looking at whether
a new drug, Ganetespib has any improvement on survival for these types of patients.